RFP
ACAD icon

Root Financial Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Root Financial Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-289
Closed -$6.43K – 425
2026
Q1 		$6.43K Sell
289
-43
-13% -$1.03K ﹤0.01% 1855
2025
Q4 		$8.87K Buy
332
+69
+26% +$1.65K ﹤0.01% 1551
2025
Q3 		$5.61K Buy
+263
New +$6.22K ﹤0.01% 1681

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Root Financial Partners's ACAD Position: Q2 2026 in Review

Root Financial Partners sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 289 shares — an estimated $6.43K sold.

Root Financial Partners first reported a position in ACAD in Q3 2025 and held it in 3 quarters. The position peaked at $8.87K in Q4 2025. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Root Financial Partners reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Root Financial Partners sold 289 Acadia Pharmaceuticals shares in Q2 2026, an estimated $6.43K.
  • Root Financial Partners first reported a position in Acadia Pharmaceuticals in Q3 2025 and held it in 3 quarters.
  • Root Financial Partners's Acadia Pharmaceuticals position peaked at $8.87K in Q4 2025.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Root Financial Partners's 13F filing for Q2 2026, filed 29 Jul 2026.